20 Years Later: A Cancer DNA Load Blood Test

Chronix Biomedical

Chronix Biomedical filed its first patent application 20 years ago on October 4, 1996. This first patent application has subsequently led to a series of exciting developments culminating in revolutionary genetic testing technology to diagnose...

By | October 4th, 2016|Chronix news|0 Comments

#TheTurningPointInCancerFight

Chronix Biomedical

Exactly 20 years ago, on 4th of October 1996, Howard Urnovitz, founder and CEO of Chronix Biomedical, an innovative biomedical company from Palo Alto (California, US), has applied for a Patent, which was the result...

By | October 4th, 2016|Chronix news|0 Comments

Chronix Biomedical welcomes moves to define new regulatory standards in liquid biopsy field

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (20 July 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, welcomes the recent moves to more clearly define US regulatory standards for the use of...

By | July 20th, 2016|Chronix news|0 Comments

Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis

Chronix Biomedical

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...

By | June 3rd, 2016|Chronix news|0 Comments

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...

By | June 1st, 2016|Chronix news|0 Comments

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to immunotherapy at the ASCO Annual Meeting

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number...

By | May 3rd, 2016|Chronix news|0 Comments

New Chronix Liquid Biopsy Test Could Save Doctors On Immunotherapy Costs

Chronix Biomedical

Offering around a month from now its circulating cell-free tumour DNA-based test to monitor.....

By | March 27th, 2015|Chronix news|0 Comments